Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Net patient service revenue	$ 242	$ 0	$ 242	$ 0
Operating expense:
Cost of patient services	97	0	97	0
Research and development	1,429	611	3,219	5,163
Selling, general and administrative	2,808	2,409	8,492	10,903
Depreciation and amortization expense	26	2	28	4
Settlement (income) expense	(94)	0	6	0
Total operating expenses	4,266	3,022	11,842	16,070
Loss from operations	(4,024)	(3,022)	(11,600)	(16,070)
Other (income) expense:
Interest income	(2)	(6)	(8)	(40)
Interest expense	0	0	0	230
Change in fair value of convertible notes payable	1,502	(1,355)	8,032	(1,014)
Change in fair value of warrant liabilities	4,963	(165)	8,481	(174)
Loss on issuance of Registered Direct Offering	0	0	730	0
Loss on consideration shares and warrants	0	0	1,277	0
Convertible note default penalty	0	0	0	849
Loss on convertible note conversions	772	127	4,239	127
Gain on exercise of warrant liabilities	(5,369)	0	(5,369)	0
Total other expense (income)	1,866	(1,399)	17,382	(22)
Net loss	(5,890)	(1,623)	(28,982)	(16,048)
Comprehensive loss:
Change in fair value of convertible note attributed to credit risk	0	(3)	0	(3)
Other comprehensive loss	0	3	0	3
Comprehensive loss	$ (5,890)	$ (1,626)	$ (28,982)	$ (16,051)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.27)	$ (0.15)	$ (1.54)	$ (1.59)
Weighted average Common Stock outstanding:
Basic and diluted (in shares)	22,231,178	10,973,697	18,881,968	10,108,859